Abstract
Ciprofloxacin was investigated in bacterial respiratory tract infections in an open multicenter study with 122 physicians. Treatment was assessed according to subjective and objective clinical symptoms. There were 683 patients in the trial. The dosage was 250 mg BID or 500 mg BID of ciprofloxacin, depending on the severity of the infection. The average duration of treatment was 9 days. The clinical assessment of ciprofloxacin treatment showed cure in 537 patients (78.6%) and improvement in 132 patients (19.3%). Only 14 patients (2.0%) were assessed as treatment failures. Adverse events, primarily gastrointestinal in nature, occurred in 42 patients; 13 of these patients (1.9%) discontinued treatment. The study results support the clinical efficacy of ciprofloxacin in the outpatient management of lower and upper respiratory tract infections. In addition, the safety of ciprofloxacin in general medical practice was substantiated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
